(Q33418305)

26 July 2017

title

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer (English)

1 reference

26 July 2017

main subject

metastatic breast cancer

1 reference

1 reference

1 reference

4

Hiroji Iwata

1 reference

26 July 2017

7

Chikako Shimizu

1 reference

26 July 2017

12

Yasuhiro Fujiwara

1 reference

26 July 2017

6

Kan Yonemori

1 reference

26 July 2017

5

Kenji Tamura

1 reference

26 July 2017

2

Masashi Ando

1 reference

26 July 2017

1

Harukaze Yamamoto

1 reference

26 July 2017

3

Kenjiro Aogi

1 reference

26 July 2017

Fumikata Hara

8

1 reference

26 July 2017

Daisuke Takabatake

series ordinal

9

1 reference

26 July 2017

Masaya Hattori

series ordinal

10

1 reference

26 July 2017

Takashi Asakawa

series ordinal

11

1 reference

26 July 2017

publication date

20 October 2014

1 reference

Japanese Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

45

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

12-18

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

Early Clinical Study of an Intermittent Schedule for Maytansine (NSC-153858): Brief Communication 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU160

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYU160

1 reference

26 July 2017

1 reference